World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
134
Citations
90707
World Ranking
2108
National Ranking
1192

Overview

Aman U. Buzdar is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research focuses broadly on biochemistry, genetics, and molecular biology, with significant work in medicine. They have contributed substantially to subfields including cancer research, oncology, radiology, nuclear medicine and imaging, genetics, and molecular biology.

The scientist's primary topics of study include breast cancer treatment studies, HER2/EGFR in cancer research, estrogen and related hormone effects, cancer genomics and diagnostics, radiomics and machine learning in medical imaging, cancer treatment and pharmacology, and advanced breast cancer therapies.

Frequent venues for publications are diverse, reflecting the multidisciplinary nature of their work. These venues include the Journal of Clinical Oncology, The Lancet, JCI Insight, Clinical Cancer Research, and Pharmacogenetics and Genomics.

Recent notable papers authored or co-authored by Aman U. Buzdar include:

  • Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,800 women from 86 randomised trials (2023, The Lancet)
  • Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action (2020, JCI Insight)
  • Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer (2022, Clinical Cancer Research)
  • Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer (2020, Pharmacogenetics and Genomics)
  • Investigating the disparate enrollment of older adults on phase I clinical trials: Evolving participation patterns of patients 65 years and older with advanced cancer on phase I trials (2020, Journal of Clinical Oncology)

The scientist has collaborated frequently with several coauthors, including:

  • Paul E. Goss
  • Lois E. Shepherd
  • Clinton Yam
  • Beatriz E. Adrada
  • Vicente Valero

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

    Anthony Howell

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

    W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan

  • Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames

  • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

    Jack Cuzick;Ivana Sestak;Michael Baum;Aman U Buzdar

  • Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

    J. M. Nabholtz;A. Buzdar;M. Pollak;W. Harwin

  • Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

    Frankie Ann Holmes;Ronald S. Walters;Richard L. Theriault;Aman U. Buzdar

  • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

    M Baum;A Buzdar;J Cuzick;J Forbes

  • Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group.

    IC Henderson;H Mouridsen;O Abe;M Abeloff

  • Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

    P. A. Greenberg;G. N. Hortobagyi;T. L. Smith;L. D. Ziegler

  • Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

    Shaheenah Dawood;Kristine Broglio;Aman U Buzdar;Gabriel N. Hortobagyi

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Breast carcinoma in men: a population-based study.

    Sharon H. Giordano;Deborah S. Cohen;Aman U. Buzdar;George Perkins

  • Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

    I. C. Henderson;H. Mouridsen;O. Abe;M. Abeloff

  • Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

    Jack Cuzick;Mitch Dowsett;Silvia Pineda;Christopher Wale

  • Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

    Mitch Dowsett;Jack Cuzick;Christopher Wale;John Forbes

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

    Jordan U. Gutterman;George R. Blumenschein;Raymond Alexanian;Hwee-Yong Yap

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Richard L. Theriault
Richard L. Theriault The University of Texas MD Anderson Cancer Center
Henry Mark Kuerer
Henry Mark Kuerer The University of Texas MD Anderson Cancer Center
George R. Blumenschein
George R. Blumenschein The University of Texas MD Anderson Cancer Center
S. Eva Singletary
S. Eva Singletary The University of Texas MD Anderson Cancer Center
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Kelly K. Hunt
Kelly K. Hunt The University of Texas MD Anderson Cancer Center
Terry L. Smith
Terry L. Smith The University of Texas MD Anderson Cancer Center
Lajos Pusztai
Lajos Pusztai Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in healthcare is easier than ever with the expansion of online education. For those interested in medical administration, online medical billing and coding courses provide a flexible option to enter this growing field without the need for extensive clinical training.

Aspiring nurses can benefit from affordable nursing programs that offer accredited coursework and practical experiences, making nursing more accessible for students with financial or location constraints. For those who seek advanced clinical roles, the cheapest online nurse practitioner programs offer a cost-effective way to become a nurse practitioner and expand patient care responsibilities.

Experienced nurses looking to advance into research or leadership roles can consider online PhD programs in nursing. These programs are designed for flexibility, allowing professionals to balance career and education while contributing to innovation and policy in healthcare.

Best Scientists Citing Aman U. Buzdar

Trending Scientists

Recently Published Articles